ABSTRACT
Biomaterials that have at least one dimension on the nanometer scale (<1 micron) are beginning to be used to encapsulate and deliver anti-cancer drugs to target areas in the body with a special emphasis on solid mass tumors. Current FDA-approved nanobiomaterials for cancer therapy that have well-defined structures include Abraxane, Daunoxome, Doxil, Genexol-PM, MM-398, and Myocet. Several additional yet-similar formulations are currently in use in Europe, China, South Korea, and India. These nanobiomaterials or nanoparticles are celebrated for their increased circulation times, relative improved efficacy and reduced side effects over freely administered anti-cancer drugs. However, major complications remain. In this chapter we review the progress that has been made in nanobiomaterial design and the additional challenges that remain in eradicating cancers using nanotechnologies that circulate in the vasculature before reaching their target.
